CINCINNATI--(BUSINESS WIRE)--Radiant Research, Inc. announced today that after only two months of recruitment efforts it has randomized 1,000 patients into the Light Study, the cardiovascular outcomes trial evaluating Orexigen Therapeutics’ investigational obesity therapeutic, Contrave® (naltrexone SR / bupropion SR). Twenty of Radiant’s US centers are participating in the study, which was designed to be conducted at approximately 300 clinical sites in the United States. Radiant centers currently represent six of the top 10 sites for the highest number of randomized patients.
